Serveur d'exploration H2N2

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Characterization and clinical evaluation of live influenza a vaccine prepared from a recombinant of the A/USSR/92/77 (H1N1) and the cold-adapted A/Ann Arbor/6/60 (H2N2) strains

Identifieur interne : 002827 ( Main/Exploration ); précédent : 002826; suivant : 002828

Characterization and clinical evaluation of live influenza a vaccine prepared from a recombinant of the A/USSR/92/77 (H1N1) and the cold-adapted A/Ann Arbor/6/60 (H2N2) strains

Auteurs : Friso Van Voorthuizen [Pays-Bas] ; Dorine Jens [Pays-Bas] ; Frans Saes [Pays-Bas]

Source :

RBID : ISTEX:BFD4166811ACC69DBA58637BFBEA902FF53F5B73

Descripteurs français

English descriptors

Abstract

Abstract: Live influenza vaccine was prepared after genetic recombination of the A/USSR/92/77 (H1N1) strain with the cold-adapted A/Ann Arbor/6/60 (H2N2) strain. The recombinant contains the genes coding for the HA and NA proteins from the A/USSR/92/77 (H1N1) strain and the genes coding for the P1, P2, P3, NP, M and NS proteins from the A/Ann Arbor/6/60 (H2N2) strain. To assess the properties of this vaccine, it was administered under double-blind conditions to 14 healthy volunteers, while another 14 healthy volunteers received placebo. The vaccine virus appeared to be sufficiently attenuated. No febrile reactions were observed. The vaccinees showed an increase in mean serum haemagglutination-inhibiting antibody level from 19 to 73 after two vaccinations. From nasal swabs and antibody responses, it was concluded that the vaccine virus showed no transmission to the placebo group under conditions of close contact. Also, the vaccine virus was found to be genetically stable. It is concluded that this live influenza virus vaccine meets the requirements for safe use in humans. However, several problems still exist which may impede a general use of live influenza vaccines.

Url:
DOI: 10.1016/0166-3542(81)90037-1


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title>Characterization and clinical evaluation of live influenza a vaccine prepared from a recombinant of the A/USSR/92/77 (H1N1) and the cold-adapted A/Ann Arbor/6/60 (H2N2) strains</title>
<author>
<name sortKey="Van Voorthuizen, Friso" sort="Van Voorthuizen, Friso" uniqKey="Van Voorthuizen F" first="Friso" last="Van Voorthuizen">Friso Van Voorthuizen</name>
</author>
<author>
<name sortKey="Jens, Dorine" sort="Jens, Dorine" uniqKey="Jens D" first="Dorine" last="Jens">Dorine Jens</name>
</author>
<author>
<name sortKey="Saes, Frans" sort="Saes, Frans" uniqKey="Saes F" first="Frans" last="Saes">Frans Saes</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:BFD4166811ACC69DBA58637BFBEA902FF53F5B73</idno>
<date when="1980" year="1980">1980</date>
<idno type="doi">10.1016/0166-3542(81)90037-1</idno>
<idno type="url">https://api.istex.fr/ark:/67375/6H6-4JF1JL7T-W/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000776</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000776</idno>
<idno type="wicri:Area/Istex/Curation">000776</idno>
<idno type="wicri:Area/Istex/Checkpoint">001441</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001441</idno>
<idno type="wicri:doubleKey">0166-3542:1980:Van Voorthuizen F:characterization:and:clinical</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:7039499</idno>
<idno type="wicri:Area/PubMed/Corpus">000574</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000574</idno>
<idno type="wicri:Area/PubMed/Curation">000574</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000574</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000501</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000501</idno>
<idno type="wicri:Area/Ncbi/Merge">001241</idno>
<idno type="wicri:Area/Ncbi/Curation">001241</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001241</idno>
<idno type="wicri:doubleKey">0166-3542:1981:Van Voorthuizen F:characterization:and:clinical</idno>
<idno type="wicri:Area/Main/Merge">002974</idno>
<idno type="wicri:Area/Main/Curation">002827</idno>
<idno type="wicri:Area/Main/Exploration">002827</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a">Characterization and clinical evaluation of live influenza a vaccine prepared from a recombinant of the A/USSR/92/77 (H1N1) and the cold-adapted A/Ann Arbor/6/60 (H2N2) strains</title>
<author>
<name sortKey="Van Voorthuizen, Friso" sort="Van Voorthuizen, Friso" uniqKey="Van Voorthuizen F" first="Friso" last="Van Voorthuizen">Friso Van Voorthuizen</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Clinical Research Department and the Human Vaccines Department, Duphar B.V., P.O. Box 2, Weesp</wicri:regionArea>
<wicri:noRegion>Weesp</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Jens, Dorine" sort="Jens, Dorine" uniqKey="Jens D" first="Dorine" last="Jens">Dorine Jens</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Clinical Research Department and the Human Vaccines Department, Duphar B.V., P.O. Box 2, Weesp</wicri:regionArea>
<wicri:noRegion>Weesp</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Saes, Frans" sort="Saes, Frans" uniqKey="Saes F" first="Frans" last="Saes">Frans Saes</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Clinical Research Department and the Human Vaccines Department, Duphar B.V., P.O. Box 2, Weesp</wicri:regionArea>
<wicri:noRegion>Weesp</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Antiviral Research</title>
<title level="j" type="abbrev">AVR</title>
<idno type="ISSN">0166-3542</idno>
<imprint>
<publisher>ELSEVIER</publisher>
<date type="published" when="1981">1981</date>
<biblScope unit="volume">1</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="107">107</biblScope>
<biblScope unit="page" to="122">122</biblScope>
</imprint>
<idno type="ISSN">0166-3542</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0166-3542</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Antibody Formation</term>
<term>Clinical Trials as Topic</term>
<term>Double-Blind Method</term>
<term>Genotype</term>
<term>Humans</term>
<term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza A Virus, H2N2 Subtype</term>
<term>Influenza A virus (genetics)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Influenza Vaccines (therapeutic use)</term>
<term>Recombination, Genetic</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Essais cliniques comme sujet</term>
<term>Génotype</term>
<term>Humains</term>
<term>Méthode en double aveugle</term>
<term>Production d'anticorps</term>
<term>Recombinaison génétique</term>
<term>Sous-type H1N1 du virus de la grippe A</term>
<term>Sous-type H2N2 du virus de la grippe A</term>
<term>Vaccins antigrippaux (immunologie)</term>
<term>Vaccins antigrippaux (usage thérapeutique)</term>
<term>Virus de la grippe A (génétique)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en">
<term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en">
<term>Influenza A virus</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr">
<term>Virus de la grippe A</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr">
<term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr">
<term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en">
<term>Antibody Formation</term>
<term>Antibody response</term>
<term>Antibody responses</term>
<term>Antibody titres</term>
<term>Attenuated</term>
<term>Biomedical press</term>
<term>Body temperature</term>
<term>Calculation purposes</term>
<term>Chnical study</term>
<term>Clinical Trials as Topic</term>
<term>Clinical signs</term>
<term>Clone</term>
<term>Coarse spray</term>
<term>Donor strain</term>
<term>Double infection</term>
<term>Double-Blind Method</term>
<term>Febrile reactions</term>
<term>First vaccination</term>
<term>Genes coding</term>
<term>Genetic recombination</term>
<term>Genotype</term>
<term>Growth properties</term>
<term>Healthy volunteers</term>
<term>Humans</term>
<term>Influenza</term>
<term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza A Virus, H2N2 Subtype</term>
<term>Influenza vaccine</term>
<term>Influenza vaccines</term>
<term>Influenza virus</term>
<term>Influenza virus vaccine</term>
<term>Influenza viruses</term>
<term>Maassab</term>
<term>Mdck cells</term>
<term>More days</term>
<term>Nasal</term>
<term>Nasal swabs</term>
<term>Original vaccine virus</term>
<term>Parent strain</term>
<term>Placebo</term>
<term>Placebo group</term>
<term>Placebo response</term>
<term>Recombinant</term>
<term>Recombination</term>
<term>Recombination, Genetic</term>
<term>Sandoz research institute</term>
<term>Second vaccination</term>
<term>Seed virus</term>
<term>Serum antibody response</term>
<term>Serum level</term>
<term>Shutoff temperature</term>
<term>Study population</term>
<term>Stuffy nose</term>
<term>Surface proteins</term>
<term>Swab</term>
<term>Third blood sample</term>
<term>Tract symptoms</term>
<term>Undetectable antibody</term>
<term>Unwanted effects</term>
<term>Vaccination</term>
<term>Vaccine</term>
<term>Vaccine group</term>
<term>Vaccine virus</term>
<term>Virus</term>
<term>Volunteer</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Essais cliniques comme sujet</term>
<term>Génotype</term>
<term>Humains</term>
<term>Méthode en double aveugle</term>
<term>Production d'anticorps</term>
<term>Recombinaison génétique</term>
<term>Sous-type H1N1 du virus de la grippe A</term>
<term>Sous-type H2N2 du virus de la grippe A</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Abstract: Live influenza vaccine was prepared after genetic recombination of the A/USSR/92/77 (H1N1) strain with the cold-adapted A/Ann Arbor/6/60 (H2N2) strain. The recombinant contains the genes coding for the HA and NA proteins from the A/USSR/92/77 (H1N1) strain and the genes coding for the P1, P2, P3, NP, M and NS proteins from the A/Ann Arbor/6/60 (H2N2) strain. To assess the properties of this vaccine, it was administered under double-blind conditions to 14 healthy volunteers, while another 14 healthy volunteers received placebo. The vaccine virus appeared to be sufficiently attenuated. No febrile reactions were observed. The vaccinees showed an increase in mean serum haemagglutination-inhibiting antibody level from 19 to 73 after two vaccinations. From nasal swabs and antibody responses, it was concluded that the vaccine virus showed no transmission to the placebo group under conditions of close contact. Also, the vaccine virus was found to be genetically stable. It is concluded that this live influenza virus vaccine meets the requirements for safe use in humans. However, several problems still exist which may impede a general use of live influenza vaccines.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Pays-Bas</li>
</country>
</list>
<tree>
<country name="Pays-Bas">
<noRegion>
<name sortKey="Van Voorthuizen, Friso" sort="Van Voorthuizen, Friso" uniqKey="Van Voorthuizen F" first="Friso" last="Van Voorthuizen">Friso Van Voorthuizen</name>
</noRegion>
<name sortKey="Jens, Dorine" sort="Jens, Dorine" uniqKey="Jens D" first="Dorine" last="Jens">Dorine Jens</name>
<name sortKey="Saes, Frans" sort="Saes, Frans" uniqKey="Saes F" first="Frans" last="Saes">Frans Saes</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002827 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002827 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    H2N2V1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:BFD4166811ACC69DBA58637BFBEA902FF53F5B73
   |texte=   Characterization and clinical evaluation of live influenza a vaccine prepared from a recombinant of the A/USSR/92/77 (H1N1) and the cold-adapted A/Ann Arbor/6/60 (H2N2) strains
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 14 19:59:40 2020. Site generation: Thu Mar 25 15:38:26 2021